4576-89-0

Basic information

• Product Name: 5-BroMoisothiazole-3-carboxylic acid
• Synonyms: 5-BroMoisothiazole-3-carboxylic acid
• CAS NO: 4576-89-0
• Molecular Formula: C₄H₂BrNO₂S
• Molecular Weight: 208.03318
• Mol File: 4576-89-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 225.0±38.0 °C(Predicted)
• Appearance: /
• Density: 2.062±0.06 g/cm3(Predicted)
• PKA: 3.13±0.10(Predicted)
• CAS DataBase Reference: 5-BroMoisothiazole-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BroMoisothiazole-3-carboxylic acid(4576-89-0)
• EPA Substance Registry System: 5-BroMoisothiazole-3-carboxylic acid(4576-89-0)

Safety Data

• Hazardous Substances Data: 4576-89-0(Hazardous Substances Data)

Upstream product

• 20493-60-1 5-bromo-3-methylisothiazole 
• 4576-94-7 5-bromo-3-(bromomethyl)isothiazole 

Downstream Products

• 1258841-09-6 (5-bromo-isothiazol-3-yl)-[2-(4-fluoro-phenyl)-pyrrolidin-1-yl]-methanone 

Relevant articles and documents

RESORCINOL DERIVATIVE AS HSP90 INHIBITOR

The present invention relates to a compound represented by formula (I) of a resorcinol derivative as an HSP90 inhibitor or pharmaceutically accepted salts thereof. The compound in the present invention has the activity of inhibiting heat shock protein HSP90. Therefore, the compound in the present invention is used to treat proliferative diseases such as cancer and neurodegenerative diseases. The present invention further provides the compounds and preparation methods for pharmaceutical compositions comprising the compounds, a method for treating diseases, and pharmaceutical compositions comprising the compounds.

AMIDO-ISOTHIAZOLE COMPOUNDS AND THEIR USE AS INHIBITORS OF 11BETA-HSD1 FOR THE TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.